Log In
Print
BCIQ
Print
Print this Print this
 

Makena (hydroxyprogesterone caproate injection) (formerly Gestiva)

Also known as: 17P

  Manage Alerts
Collapse Summary General Information
Company AMAG Pharmaceuticals Inc.
DescriptionLong-acting form of a naturally occurring progesterone, 17 alpha-hydroxyprogesterone caproate (17P)
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationUterine contractions
Indication DetailsPrevent preterm birth; Reduce risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of at least one spontaneous preterm birth
Regulatory Designation U.S. - Accelerated Approval (Reduce risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of at least one spontaneous preterm birth);
U.S. - Orphan Drug (Prevent preterm birth)
Partner AMAG Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,024.0M

$600.0M

$350.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today